利用水疱性口炎病毒载体(rVSV载体)平台开发SARS-CoV-2疫苗:IIBR-100在健康成人中的1/2期安全性和免疫原性
在以色列八个临床中心开展1/2期随机观察者盲安慰剂对照研究,评估rVSV-SARS-CoV-2-S疫苗IIBR-100在健康年轻和年长成人中的安全性与免疫原性;1期未观察到安全性问题,2期常见不良事件为注射部位疼痛、疲劳和头痛;1×10^7 PFU/mL和1×10^8 PFU/mL初免-加强方案安全、耐受良好且具有免疫原性。
要点
- 1期(N=82)未观察到安全性问题,研究继续进入2期。
- 2期(N=762)常见不良事件为注射部位疼痛20-64%、疲劳21-33%、头痛15-22%。
- 最高剂量组中和抗体和结合抗体滴度分别在第35天和第42天达峰。
核心结论
- IIBR-100疫苗以1×10^7 PFU/mL和1×10^8 PFU/mL剂量进行初免-加强方案,在健康成人中安全、耐受良好且具有免疫原性。
研究设计与样本
- 1/2期随机观察者盲安慰剂对照研究(ClinicalTrials.gov: NCT04608305),从以色列八个临床中心招募健康年轻(18-55岁)和年长(56-85岁)成人。
- 1期测试低剂量(1×10^5 PFU)、中剂量(1×10^6 PFU)和高剂量(1×10^7 PFU)单剂方案,仅低剂量组额外加强一剂。
- 2期基于1期结果仅测试中剂量和高剂量初免-加强方案以及额外最高剂量(1×10^8 PFU)。
- 参与者随机分配至IIBR-100或安慰剂,自末次接种起随访12个月以评估安全性和免疫原性。
主要发现
- 1期(N=82)未观察到安全性问题,研究因此进入2期。
- 2期(N=762)中,两个年龄组最常见不良事件包括注射部位疼痛(20-64%)、疲劳(21-33%)和头痛(15-22%)。
- 最高剂量组中和抗体滴度在第35天达峰,结合抗体滴度在第42天达峰。
- 中和抗体和结合抗体(刺突蛋白和RBD)的血清转化率至第56天达到最高水平。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the safety and immunogenicity of the IIBR-100 (rVSV-SARS-CoV-2-S) vaccine, a recombinant VSV-ΔG-spike vaccine against SARS-CoV-2 virus. METHODS: In a phase 1/2, randomized, observer-blind, placebo-controlled study (ClinicalTrials.gov: NCT04608305), healthy younger (18-55 years) and older (56-85 years) adults were recruited from eight clinical sites in Israel. In the phase 1 study, low (1 × 105 PFU), mid (1 × 106 PFU), and high doses (1 × 107 PFU) of IIBR-100 were tested in a single-dose treatment regimen, with an additional booster dose for the low-dose group only. Based on the phase 1 study results, only mid- and high-dose prime-boost regimens alongside an additional top dose (1 × 108 PFU) were tested in the phase 2 study. Participants, randomly assigned to either IIBR-100 or placebo, were followed for 12 months from the last vaccination for safety and immunogenicity outcomes. FINDINGS: No safety concerns were observed in the phase 1 study (N = 82); therefore, the study moved on to phase 2. In phase 2 (N = 762), for both age groups, the most common AEs included injection-site pain (20-64 %), fatigue (21-33 %), and headache (15-22 %). In the top-dose group, neutralizing and binding antibody titers peaked on Days 35 and 42, respectively; seroconversion rates reached maximal levels by Day 56 for neutralizing antibody and binding antibody (spike and RBD). INTERPRETATION: The IIBR-100 vaccine against SARS-CoV-2 in prime-boost regimens at 1 × 107 PFU/mL and 1 × 108 PFU/mL doses is safe, well tolerated, and immunogenic in healthy adults. CLINICAL TRIAL REGISTRY: This trial is registered at ClinicalTrials.gov (NCT04608305) and in the trial registry of the Israeli Ministry of Health website.
引用
- Caraco Y, Madar-Balakirski N, Ben-Ami E, et al. Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults. Vaccine. 2025. PMID: 41106035. doi:10.1016/j.vaccine.2025.127837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。